Glenmark launches Lobeglitazone in India for Uncontrolled Type 2 Diabetes in adults
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
This new initiative will cater to the increasing number of patients in Karnataka in need of heart and lung Failure management and transplant
The two-day meeting in the city was organized in collaboration with the University of Birmingham, Christian Medical College Ludhiana, and Birmingham Clinical Trials Unit
Dr. Bunker will focus on leading Research and Development (R&D) in San Diego, advancing the preclinical pipeline and optimizing the Company’s Integrated Discovery Engine.
Patients with moderate or elevated risk in the test should immediately consult a cardiologist for further diagnosis and workup
The companies have also initiated a Phase 1/2/3 study NCT05543616 to evaluate the safety, tolerability, and immunogenicity of different doses
Transformation to pure-play Innovative Medicines company nears completion
The companies will leverage their respective proprietary technology platforms
The startup plans to provide free technology to dental clinics upon registration.
Subscribe To Our Newsletter & Stay Updated